AbbVie (ABBV)
(Delayed Data from NYSE)
$168.03 USD
-2.25 (-1.32%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $168.00 -0.03 (-0.02%) 6:00 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Price, Consensus and EPS Surprise
ABBV 168.03 -2.25(-1.32%)
Will ABBV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ABBV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABBV
AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU
AbbVie (ABBV) Gains As Market Dips: What You Should Know
ABBV: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
The Zacks Analyst Blog Highlights Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian
Other News for ABBV
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis
AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer
AbbVie to Host Second-Quarter 2024 Earnings Conference Call
AbbVie, Genmab blood cancer therapy endorsed in EU
7 Dividend Kings to Buy With Your Roth IRA Money in 2024